ATXI Sets Virtual Annual Meeting to Elect Directors, Ratify Auditor

TL;DR

**ATXI's virtual annual meeting is a routine governance check, but the 1-for-75 reverse stock split and preferred stock's outsized voting power are red flags for common shareholders.**

AI Summary

Avenue Therapeutics, Inc. (ATXI) is holding its Annual Meeting of Stockholders virtually on December 30, 2025, at 10:00 a.m. Eastern Time. Stockholders will vote on the election of six directors for a one-year term and the ratification of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025. As of the November 25, 2025 record date, there were 3,183,426 shares of common stock and 250,000 shares of Class A Preferred Stock outstanding, with Class A Preferred Stock holding 14.0 votes per share due to a 1-for-75 reverse stock split effected on April 26, 2024. The company emphasizes virtual attendance to encourage broader participation and reduce costs. The Board of Directors recommends voting 'FOR' all director nominees and 'FOR' the ratification of KPMG LLP.

Why It Matters

This DEF 14A filing outlines the critical governance decisions for Avenue Therapeutics, impacting investor confidence and operational oversight. The election of six directors will shape the company's strategic direction and accountability, directly affecting future drug development and financial performance. Ratifying KPMG LLP ensures independent financial scrutiny, crucial for maintaining transparency and investor trust in a competitive biotech landscape. For employees, a stable and well-governed company provides job security and clear leadership, while customers rely on effective governance to ensure product quality and ethical practices in drug development.

Risk Assessment

Risk Level: medium — The company effected a 1-for-75 reverse stock split on April 26, 2024, which often signals underlying financial distress or a struggle to maintain listing requirements. Additionally, the Class A Preferred Stock holds significantly disproportionate voting power, with 14.0 votes per share compared to common stock's one vote, potentially diluting common shareholder influence.

Analyst Insight

Investors should carefully review the director nominees' qualifications and consider the implications of the Class A Preferred Stock's voting power on common shareholder influence. Given the recent reverse stock split, a deeper dive into ATXI's financial health and strategic pipeline is warranted before making any investment decisions.

Key Numbers

• 1-for-75 — Reverse Stock Split Ratio (Effected on April 26, 2024, impacting share count and price)
• 14.0 votes — Class A Preferred Stock Voting Power (Per share, significantly higher than common stock)
• December 30, 2025 — Annual Meeting Date (Date stockholders will vote on proposals)
• November 25, 2025 — Record Date (Date for determining eligible voters for the Annual Meeting)
• 6 — Number of Directors (To be elected for a one-year term)
• 3,183,426 — Common Stock Shares Outstanding (As of the November 25, 2025 Record Date)
• 250,000 — Class A Preferred Stock Shares Outstanding (As of the November 25, 2025 Record Date)

Key Players & Entities

• AVENUE THERAPEUTICS, INC. (company) — Registrant for DEF 14A filing
• KPMG LLP (company) — Independent registered public accounting firm for 2025
• Alexandra MacLean, M.D. (person) — Chief Executive Officer and proxy appointee
• David Jin (person) — Interim Chief Financial Officer, Chief Operating Officer, Corporate Secretary, and proxy appointee
• Securities and Exchange Commission (regulator) — Regulatory body for proxy statement rules
• VStock Transfer, LLC (company) — Transfer agent for Avenue Therapeutics
• $3,183,426 (dollar_amount) — Shares of common stock outstanding on Record Date
• $250,000 (dollar_amount) — Shares of Class A Preferred Stock outstanding on Record Date

FAQ

Industry Context

Avenue Therapeutics operates in the biopharmaceutical sector, a highly competitive and research-intensive industry. Success is driven by the ability to develop and gain regulatory approval for novel therapies. The industry is characterized by significant R&D investment, long development cycles, and substantial regulatory hurdles imposed by bodies like the FDA. Companies often face challenges in securing funding and navigating patent landscapes.

Regulatory Implications

As a biopharmaceutical company, Avenue Therapeutics is subject to stringent regulations from health authorities like the FDA. Approval processes for new drugs are lengthy and costly, with a high failure rate. Post-market surveillance and compliance with manufacturing standards (cGMP) are also critical. Any delays or setbacks in regulatory reviews can significantly impact the company's timeline and financial viability.

What Investors Should Do

1. Review director nominees and vote 'FOR' their election.
2. Vote 'FOR' the ratification of KPMG LLP as the independent auditor.
3. Understand the voting power of Class A Preferred Stock.
4. Note the impact of the 1-for-75 reverse stock split.

Key Dates

• 2025-12-30: Annual Meeting of Stockholders — Stockholders will vote on the election of directors and ratification of the independent auditor.
• 2025-11-25: Record Date — Determines which stockholders are eligible to vote at the Annual Meeting.
• 2024-04-26: Reverse Stock Split — A 1-for-75 reverse stock split was effected, impacting the number of outstanding shares and potentially share price.

Glossary

DEF 14A

A proxy statement filing required by the SEC for companies holding annual meetings of shareholders, detailing information about the meeting, board of directors, executive compensation, and voting matters. (This document provides the basis for the analysis of the company's governance and upcoming shareholder decisions.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive dividends, vote on corporate matters, or receive other distributions. (Establishes the pool of eligible voters for the December 30, 2025 Annual Meeting.)

Independent Registered Public Accounting Firm

An external audit firm hired by a company to conduct an independent examination of its financial statements. (KPMG LLP is proposed for ratification, indicating their role in auditing the company's financial health for the year ending December 31, 2025.)

Class A Preferred Stock Voting Power

The voting rights associated with shares of Class A Preferred Stock, which in this case is significantly higher per share than common stock due to a reverse stock split. (Highlights a potential concentration of voting power with preferred stockholders, influencing the outcome of shareholder votes.)

Virtual Only Format

The annual meeting will be conducted entirely online, without a physical location. (A strategy to increase stockholder participation and reduce costs, but may limit direct interaction for some shareholders.)

Year-Over-Year Comparison

This filing pertains to the 2025 Annual Meeting, and direct comparisons to a previous year's filing are not possible without access to prior DEF 14A documents. However, key information points such as the record date (November 25, 2025), the number of directors to be elected (six), and the proposed auditor (KPMG LLP) are specific to this year's meeting. The mention of a 1-for-75 reverse stock split effected on April 26, 2024, indicates a significant structural change that would have been reflected in previous financial reporting and disclosures.

Filing Documents

• atxi20251204_def14a.htm (DEF 14A) — 473KB
• a01.jpg (GRAPHIC) — 134KB
• a02.jpg (GRAPHIC) — 129KB
• at.jpg (GRAPHIC) — 9KB
• tsr2025a.jpg (GRAPHIC) — 33KB
• 0001437749-25-037023.txt ( ) — 1743KB
• atxi-20241231.xsd (EX-101.SCH) — 5KB
• atxi-20241231_def.xml (EX-101.DEF) — 3KB
• atxi-20241231_lab.xml (EX-101.LAB) — 4KB
• atxi-20241231_pre.xml (EX-101.PRE) — 2KB
• atxi20251204_def14a_htm.xml (XML) — 76KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 16 Summary Compensation Table 16 Narrative to Summary Compensation Table 17 i Table of Contents Equity Awards 17 Outstanding Equity Awards at 2024 Fiscal Year End 18 401(k) Plan 18 Clawback Policy 18 DIRECTOR COMPENSATION 19 Director Compensation Program 19 Director Compensation Table 19 PAY VERSUS PERFORMANCE DISCLOSURE 20 Analysis of the Information Presented in the Pay Versus Performance Table 21 RELATED-PERSON TRANSACTIONS 22 STOCK OWNERSHIP OF OUR DIRECTORS, EXECUTIVE OFFICERS, AND 5% BENEFICIAL OWNERS 25 EQUITY COMPENSATION PLAN INFORMATION 26 PROPOSAL NO. 1 ELECTION OF DIRECTORS; NOMINEES 27 PROPOSAL NO. 2 RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 28 ADDITIONAL INFORMATION 29 Householding of Annual Meeting Materials 29 Stockholder Proposals for Our 2026 Annual Meeting 29 Other Matters 29 Solicitation of Proxies 29 Incorporation of Information by Reference 30 ii Table of Contents QUESTIONS AND ANSWERS Q: What is the purpose of the Annual Meeting? A. At the Annual Meeting, our stockholders will act upon the matters outlined in the Notice of Annual Meeting of Stockholders accompanying this proxy statement, including (i) the election of six directors for a term of one year until our 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified in accordance with our Second Amended and Restated Bylaws ("Bylaws"), (ii) ratifying the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2025, and (iii) transacting any other business that may properly come before the Annual Meeting or any postponement or adjournment thereof. Q: How can I attend the Annual Meeting and why is the Company holding the Annual Meeting in a virtual only format? A. We are holding the Annual Meeting in a virtual format, rather than a

View Full Filing

View this DEF 14A filing on SEC EDGAR